Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
361 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (3)

Medical Condition

  • Show all (860)
  • Autoimmune Disorders (1)
  • Blood Disorders (4)
    • (-) Amyloidosis (2)
  • Cancer (750)
    • Bladder Cancer (13)
    • Brain Cancer (24)
    • Breast Cancer (72)
    • Gastrointestinal (16)
    • Gynecologic Cancer (33)
    • Head and Neck Cancer (4)
    • Kidney Cancer (8)
    • Leukemia (79)
    • Liver Cancer (11)
    • Lung Cancer (65)
    • Lymphoma (46)
    • Multiple Myeloma (31)
    • Pancreatic Cancer (22)
    • Prostate Cancer (36)
    • Sarcoma (25)
    • Skin Cancer (30)
    • Solid Tumors (44)
    • (-) Thyroid Cancer (1)
    • Uveal Melanoma (7)
  • COVID-19 (Coronavirus) (1)
  • Diabetes (2)
  • Ear, Nose and Throat (1)
  • Endocrine & Metabolic Disease (1)
  • Gastrointestinal and Digestive Diseases (2)
  • Healthy Volunteers (8)
  • Liver Disease (1)
  • Neurological Disorders (34)
  • Obesity (1)
  • Obstetrics & Gynecology (6)
  • Pediatrics (42)
  • Psychiatric Disorders (1)
  • Surgery (1)
  • Transplant (3)
  • Urology (1)
Displaying 1 - 3 of 3

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Condition: Cancer / Thyroid Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
This is a study designed for patients with medullary thyroid cancer. Treatment will consist of a drug called Ponatinib. Ponatinib is an investigational agent that blocks abnormal cancer proteins and therefore harms cancer cells. It was recently approved by the Food…
Read More

Study For Previously Treated Patients Of Light-Chain Amyloidosis Using Study Drug Carfilzomib

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects that have been previously treated for systemic light chain (AL)amyloidosis (a disease in which abnormal protein deposits can damage organs and tissues in your body) and nowrequire further treatment. The main purpose of this study is to evaluate the safety and determine the maximum tolerated dose of aninvestigational new…
Read More

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Condition: Blood Disorders / Amyloidosis
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to test for any good and bad effects of the study drug called isatuximab. Isatuximab may or may not improve your AL amyloidosis, but it could also cause side effects. Isatuximab is not approved by the Food and Drug Administration (FDA). Isatuximab has been shown to have good effects in some patients with recurring multiple…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science